High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine
Open Access
- 1 August 1985
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 28 (2), 265-273
- https://doi.org/10.1128/aac.28.2.265
Abstract
New high-pressure liquid chromatographic methods for determining concentrations of arabinosyladenine (Ara-A), its 5'-monophosphate (Ara-AMP), and arabinosylhypoxanthine (Ara-H) in plasma and urine are presented. A fluorescence detector is used for Ara-A and Ara-AMP, which are first converted to highly fluorescent derivatives with chloroacetaldehyde. This increases sensitivity greatly over previous methods. The sensitivities of the methods (in micrograms per milliliter) are as follows: in plasma, Ara-AMP, 0.002; Ara-A, 0.0015; and Ara-H, 0.35; and in urine, 9 times these values, respectively. Drug concentration data are also presented, which were obtained after doses of Ara-AMP were given intramuscularly to two patients treated with this drug for severe herpes zoster. One patient was given 13 mg of Ara-AMP per kg of body weight once daily, and the other was given 6.5 mg/kg twice daily. Peak Ara-AMP and Ara-A levels in plasma occurred within 1 h after the doses, and neither exceeded 2 micrograms/ml. Ara-AMP and Ara-A concentrations in plasma fell to less than 0.01 micrograms/ml in both patients by 4 to 6 h after the doses. Peak Ara-H concentrations in plasma occurred within 1 to 2 h after doses and were 21 micrograms/ml in patient 1 and 2. The highest concentration of Ara-AMP in urine was 0.09 micrograms/ml. The highest Ara-A concentration in urine was 62 micrograms/ml, and the highest Ara-H concentration in urine was 1,080 micrograms/ml. An interfering substance of unknown nature, cochromatographing with Ara-H, was encountered sporadically in urine samples. An algorithm based on differential spectrophotometry to identify and correct for this problem is described. Estimates of the renal clearances of Ara-AMP, Ara-A, and Ara-H are also given.This publication has 15 references indexed in Scilit:
- Early Vidarabine Therapy to Control the Complications of Herpes Zoster in Immunosuppressed PatientsNew England Journal of Medicine, 1982
- Intramuscular or Intralipomatous Injections?New England Journal of Medicine, 1982
- Vidrabine therapy of varicella in immunosuppressed patientsThe Journal of Pediatrics, 1982
- Reversed-phase high-performance liquid chromatographic method to determine vidarabine and hypoxanthine arabinoside in biological fluidsJournal of Chromatography B: Biomedical Sciences and Applications, 1982
- Determination of adenosine in normal human plasma and serum by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1982
- Effect of Liver Disease on Pharmacokinetics and Toxicity of 9- -D-Arabinofuranosyladenine-5'-PhosphateThe Journal of Infectious Diseases, 1981
- Pharmacology, Tolerance, and Antiviral Activity of Vidarabine Monophosphate in HumansAntimicrobial Agents and Chemotherapy, 1980
- Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failureAntimicrobial Agents and Chemotherapy, 1980
- Simple Sensitive Microbioassay for Adenine Arabinoside and Hypoxanthine Arabinoside in Human PlasmaAntimicrobial Agents and Chemotherapy, 1978
- High-performance liquid chromatography of adenine and hypoxanthine arabinosidesJournal of Chromatography A, 1977